RICHMOND, Calif. — February 3, 2026 — Leads & Copy — Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced the pricing of an underwritten offering. The offering includes 35,190,292 shares of its common stock and pre-funded warrants to purchase 17,787,033 shares of its common stock, together with accompanying warrants to purchase 52,977,325 shares of its common stock.
The combined offering price of each share of common stock and accompanying warrant is $0.4719. The combined offering price of each pre-funded warrant and accompanying warrant is $0.4619. The common stock and pre-funded warrants are being sold in combination with an accompanying warrant to purchase one share of common stock issued for each share of common stock or pre-funded warrant sold.
The accompanying warrant has an exercise price of $0.4719 per share, will become exercisable six months from the date of issuance and will expire five and a half years from the date of issuance.
Sangamo also agreed to reduce the exercise price on outstanding warrants to purchase 23,809,523 shares of common stock held by an investor from $1.00 to $0.4719 and extend the term of such warrants to five and a half years from the date of issuance of the securities in the offering, with such warrants to become exercisable six months from the date of issuance of the securities in the offering.
All of the securities in the offering are to be sold by Sangamo. The offering is expected to close on or about February 4, 2026, pending customary closing conditions.
The gross proceeds to Sangamo from this underwritten offering are expected to be approximately $25.0 million, before deducting the underwriting discount and other estimated offering expenses. Sangamo intends to use the net proceeds from the offering for working capital and general corporate purposes.
Cantor and Wells Fargo Securities are acting as joint book-running managers for the offering.
A shelf registration statement on Form S-3 relating to the offering of the securities was previously filed with the SEC and subsequently declared effective by the SEC. The offering is being made solely by means of a prospectus. A final prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website.
Sangamo Therapeutics is a genomic medicine company dedicated to translating ground-breaking science into medicines that transform the lives of patients and families afflicted with serious neurological diseases who do not have adequate or any treatment options. Sangamo believes that its zinc finger epigenetic regulators are ideally suited to potentially address devastating neurological disorders and that its capsid discovery platform can expand delivery beyond currently available intrathecal delivery capsids, including in the central nervous system. Sangamo’s pipeline also includes multiple partnered programs and programs with opportunities for partnership and investment.
Source: Sangamo Therapeutics, Inc.
